1. Introduction {#sec1-bioengineering-04-00017}
===============

Therapeutic products (vaccines, antibodies, etc.) are subject to exponential demands and cost-lowering process improvements, leading to the intensification of growth conditions in the bio-pharmaceutical industry and the sharp increase of the related market economy. For instance, monoclonal antibody (MAb) market amounts to several billion dollars and is still increasing.

To improve bioprocess yield and repeatability, monitoring and control tools are required. The latter implies the availability of dynamic models, which can predict the process trajectory and support the design of software sensors or control strategies. Previous optimization studies of hybridoma cell cultures for MAb production were usually conducted using simple mathematical models based on macroscopic reaction schemes such as in \[[@B1-bioengineering-04-00017],[@B2-bioengineering-04-00017]\].

More recently, a macroscopic model with kinetics accounting for overflow metabolism, where glucose and glutamine are the main substrates, was proposed in \[[@B3-bioengineering-04-00017]\]. Indeed, cell respiratory capacity is limited \[[@B4-bioengineering-04-00017]\]. Therefore, depending on the substrate concentrations, cell metabolism follows two possible pathways: the respirative regime if the respiratory capacity is sufficient to oxidize the whole substrate amount or the respiro-fermentative regime if this substrate amount is in excess with respect to the available oxidative capacity, thus leading to the formation of growth-inhibiting by-products (respectively lactate from glucose and ammonia from glutamine). The main drawback of such complex kinetic models is however the relatively large number of parameters and the necessity to achieve experiments in specific conditions so as to trigger the phenomena (activation, saturation or inhibition) reflected in the model.

A more practical alternative is to directly deduce the model structure from the available data, assuming that the data sufficiently cover the process operating range. In \[[@B5-bioengineering-04-00017]\], Principal Component Analysis (PCA) is used to determine the minimum number of reactions required to interpret the data. This methodology was further extended in \[[@B6-bioengineering-04-00017]\], where an insightful geometric interpretation is provided, and maximum likelihood principal component analysis (MLPCA) is used to estimate the reaction number and stoichiometric matrix. In this study, the latter approach is applied to the culture of hybridoma cells in sequential batch reactors (SBR). This mode of operation is common in industrial practice, and poses the question of the information content of data sets collected during the several batches. Before embarking in the analysis of actual experimental data, synthetic data are first generated with a process simulator, with the possibility of varying the initial conditions of the batches and the data sampling rate within each single batch. The methodology is subsequently applied to real-life experimental data, with a better grasp of the data information content.

The main contribution of this study is threefold: A simple dynamic model of cultures of hybridoma cells in SBR is developed and validated with experimental data. Confidence intervals for the parameters and the estimated trajectories are provided.A systematic model identification procedure, based on rigorous yet simple to use tools---MLPCA to determine the stoichiometry, nonlinear least squares to identify the parameters of the kinetic laws, sensitivity analysis and Monte Carlo analysis to infer the confidence intervals---is assessed in a real case study, showing good performance and promise for future applications.The simple dynamic model is further exploited to optimize the medium renewal strategy in the sequential batches.

This paper is organized as follows. [Section 2](#sec2-bioengineering-04-00017){ref-type="sec"} reviews the basic concepts of verflow metabolism and mathematical modeling using principal component analysis. [Section 3](#sec3-bioengineering-04-00017){ref-type="sec"} presents the experimental case study and process operating conditions. The dynamic model of hybridoma sequential batch cultures is derived in [Section 4](#sec4-bioengineering-04-00017){ref-type="sec"} and parameters are identified from experimental data in [Section 5](#sec5-bioengineering-04-00017){ref-type="sec"}. Subsequently, [Section 6](#sec6-bioengineering-04-00017){ref-type="sec"} develops a parametric sensitivity analysis and proposes further model simplifications. The simplified model is identified and cross-validated with two different data sets in [Section 7](#sec7-bioengineering-04-00017){ref-type="sec"}. Finally, the dynamic model is used to optimize the culture medium renewal time and composition in [Section 8](#sec8-bioengineering-04-00017){ref-type="sec"} while conclusions are drawn in [Section 9](#sec9-bioengineering-04-00017){ref-type="sec"}.

2. Dynamic Modeling of Hybridoma Cultures {#sec2-bioengineering-04-00017}
=========================================

This section first reviews the basic concept of overflow metabolism and then presents a systematic procedure to infer candidate macroscopic models from principal component analysis of the data at hand.

2.1. Overflow Metabolism {#sec2dot1-bioengineering-04-00017}
------------------------

The main physiological feature of hybridoma resides in their primary metabolism or, more precisely, in their catabolism, presenting the following main pathways: The glycolysis which is a series of degradation reactions of glucose (the main substrate) taking place in the cytoplasm and leading to a final product, i.e., pyruvate.The Krebs cycle, also called the tricarboxylic acids (*TCA*) cycle or citric acids cycle, which takes place inside the mitochondrions and uses pyruvate to product the cells energy units (Adenosine triphosphate or *ATP*) and reduced cofactors (typically *NADH* and *FADH*).The electron transport, still taking place in mitochondrions and producing *ATP* from the reduced cofactors.The fermentative pathway which, in oxygen limitation, produces typical products like lactate from pyruvate in the cytoplasm.

Cell catabolism is characterized by a limited energy production (i.e., the Krebs cycle has a limited capacity) principally used for cell growth and division. This limitation comes from the capacity to oxidize the main nutrients: glucose (main carbon source) and glutamine (main nitrogen source). The excess amounts of these nutrients are assumed to follow other metabolic pathways more commonly known as "fermentation", producing a side byproduct.

This "Overflow Metabolism" or "short-term Crabtree effect" \[[@B4-bioengineering-04-00017],[@B7-bioengineering-04-00017],[@B8-bioengineering-04-00017],[@B9-bioengineering-04-00017],[@B10-bioengineering-04-00017],[@B11-bioengineering-04-00017]\], is typically observed with yeast, bacteria and animal cell cultures. Depending on the case, it leads to the production of ethanol, acetate and lactate/ammonium as side byproducts. Several descriptions of this switching mechanism have been proposed in the literature (for instance in \[[@B10-bioengineering-04-00017]\]) but this phenomenon remains not well understood.

The byproduct formation usually inhibits the oxidative capacity of the cells, slowing down growth for increasing concentrations. In turn, it depends on the oxidative capacity of the cells and on the medium composition.

A generic mechanistic model that would, in principle, allow the representation of the culture of different strains presenting overflow metabolism, can be described through the following main reactions:

*j*th substrate consumption: $$k_{Si}S_{j}\overset{\phi_{S}}{\rightarrow}k_{Xi}X + k_{Pi}P_{j}$$ *j*th substrate overflow: $$k_{Si + 1}S_{j}\overset{\phi_{Over - S}}{\rightarrow}k_{Xi + 1}X + k_{Pi + 1}P_{j}$$ *j*th byproduct consumption: $$k_{Pi + 2}P_{j}\overset{\phi_{P}}{\rightarrow}k_{Xi + 2}X$$ where *X*, *S~j~* and *P~j~* are the concentrations of cell biomass, *j*th substrate and *j*th side byproduct, respectively. The *k~ni~* coefficients represent the yield (or pseudo-stoichiometric) coefficients of component *n* in reaction *i*. Overflow metabolism assumption involves that, for each concerned substrate, these reactions take place in pairs (1a and 1b) or triplets (1a--1c) if the considered byproduct can be reconsumed by the biomass as a substitute substrate source when the oxidative capacity is not fully exploited.

Indeed, Sonnleitner and Käppeli \[[@B12-bioengineering-04-00017]\] assume that the cell oxidative capacity rules the general metabolism, following a bottleneck effect. During a culture, the cells are likely to change their metabolism depending on the exploitation of the respiratory capacity. At low substrate uptake rate (substrate concentrations are below critical levels *S* \< *S~crit~* and *φ~S~* \< *φ~Smax~*), substrate is consumed with biomass growth and a relatively low metabolite byproduct production (1a) without overflow, which is defined as respiratory metabolism and the consequent remaining respiratory capacity can be used to oxidize byproduct as substitute carbon source as in (1c).

At high substrate uptake rate (substrate concentration is above critical level *S* \> *S~crit~* and *φ~S~* \> *φ~Smax~*), the respiratory capacity is saturated, resulting in overflow metabolism towards excess metabolite production (reactions (1a) and (1b)). The state at which overflow metabolism is initiated (*S* = *S~crit~* and *φ~S~* = *φ~Smax~*) is referred to as critical metabolism. For instance, yeast metabolism is described by the bottleneck assumption of Sonnleitner and Käppeli \[[@B12-bioengineering-04-00017]\], as illustrated in [Figure 1](#bioengineering-04-00017-f001){ref-type="fig"}.

This model was exploited in \[[@B13-bioengineering-04-00017],[@B14-bioengineering-04-00017],[@B15-bioengineering-04-00017]\] for robust control purposes. Based on a similar model, references \[[@B16-bioengineering-04-00017],[@B17-bioengineering-04-00017]\] suggested practical ways to estimate state variables such as biomass, glucose or acetate in bacteria cultures using software sensors. Recently, reference \[[@B3-bioengineering-04-00017]\] proposed a dynamic model of hybridoma fed-batch cultures based on a double overflow mechanism, one linked to glucose, and the other to glutamine, with good prediction capabilities.

2.2. Systematic Modeling Procedure {#sec2dot2-bioengineering-04-00017}
----------------------------------

In contrast with the previous modeling approach which is based on past experience and a priori knowledge of the metabolic network, it is now suggested to derive a model based mostly on the information content of available data sets. This can be particularly relevant when the model structure is uncertain and experimental data sets are available that can be analyzed to extract information on the reaction stoichiometry and kinetics.

First, we recall that bioprocesses can be represented by macroscopic reaction schemes involving *M* reactions between *N* components under the following generic form \[[@B18-bioengineering-04-00017]\]: $${\sum\limits_{i \in \Re_{j}}{( - k_{ij})\xi_{i}}}\overset{\phi_{j}(\xi,\vartheta_{j})}{\rightarrow}{\sum\limits_{i \in \wp_{j}}{(k_{ij})\xi_{j}}}$$ where $\Re_{j}$ (respectively, $\wp_{j}$) denotes the set of reactants (or products) in the "*j*th" reaction. The parameters *k~ij~* are pseudo-stoichiometric coefficients while $\phi_{j}$ is the corresponding reaction rate.

Applying mass balances to (2), the following ordinary differential equation system is obtained: $$\frac{d\xi(t)}{dt} = K\phi(\xi,\vartheta) + \upsilon(\xi,t)$$ where *K* is the pseudo-stoichiometric matrix and $\upsilon$ represents the transport term taking dilutions, input feeds and gaseous outflows into account. $\vartheta$ is the vector containing all the kinetic parameters.

The number of components *N* is generally larger than the number of reactions *M* so that the rank of the stoichiometric matrix *K* is assumed to be *M*. For instance, in \[[@B3-bioengineering-04-00017]\], *M = 5* and *N = 6*.

Defining the transport-free state evolution $\xi_{f}$ and integrating (3) between two consecutive measurement times lead to the following expression: $$\xi_{f_{i}}^{\Delta} = K{\int\limits_{t_{i}}^{t_{i + 1}}{\phi(\tau)d\tau}}$$ where $\xi_{f_{i}}^{\Delta}$ is the differential transport-free state vector. As discussed in \[[@B6-bioengineering-04-00017]\], Equation (4) expresses that $\xi_{f_{i}}^{\Delta}$ is contained in a *M*-dimensional linear subspace, and MLPCA allows to determine subspaces of increasing dimensions *p* explaining a noisy data set (and therefore reaction schemes of increasing detail explaining the experimental data). A systematic procedure can therefore be developed, which selects the smallest value of *p* that allows a thorough interpretation of the data up to a given confidence level, minimizing a log-likelihood cost: $$J_{p} = {\sum\limits_{i = 1}^{n_{S}}{(\xi_{f,m_{i}}^{\Delta} - {\hat{\xi}}_{f}^{\Delta,p}}})^{T}{(Q_{i}^{\Delta})}^{- 1}(\xi_{f,m_{i}}^{\Delta} - {\hat{\xi}}_{f}^{\Delta,p})$$ where *n~s~* is the number of measured vector samples and $\xi_{f,m_{i}}^{\Delta}$ is the noisy measurement of $\xi_{f}^{\Delta}$, with an error covariance matrix $Q_{i}^{\Delta}$ and ${\hat{\xi}}_{f}^{\Delta,p}$ is its maximum-likelihood (ML) estimate by the reduced p-dimensional linear model \[[@B6-bioengineering-04-00017]\]. *Jp* is a decreasing function of *p* which is always smaller or equal to the log-likelihood cost *J\** of the true nonlinear model. Since *J\** is known to have a chi-square distribution with $n_{S}xN$ degrees of freedom \[[@B19-bioengineering-04-00017]\]. The number of reaction is just chosen as the smallest *p* such that the log-likelihood cost *Jp* is smaller or equal to the range of a χ${}_{n_{S}xN}^{2}$-distributed random variable.

Once the number of reactions is determined, the resulting *N* by *p* affine subspace basis $\hat{\rho}$ can be used to estimate a stoichiometric matrix $\hat{K}$, which is a linear combination of the basis vectors, i.e., $$\hat{K} = \hat{\rho}G$$ with *G* a *p* by *p* regular matrix.

For a complete estimation of the stoichiometry, *p* biological constraints have to be imposed in each column of $\hat{K}$ (for instance the fact that a specific reactant or product is involved in only one reaction).

3. Experimental Case Study---Materials and Methods {#sec3-bioengineering-04-00017}
==================================================

3.1. Operating Conditions {#sec3dot1-bioengineering-04-00017}
-------------------------

In the framework of this study, six sequential suspended hybridoma batch cultures of 2 hybridoma strains (called, for the sake of confidentiality, HB1 and HB2) were performed in two series of three 200 mL T-flasks. In this protocol, at the initial time of each batch, biomass is kept in the reactor, while the metabolites (lactate, ammonia and monoclonal antibodies) are withdrawn and the substrate concentrations (glucose and glutamine) are set to prescribed values (respectively ranging between 6 and 7 g/L, and 0.3 and 0.4 g/L). The end-of-batch viable and dead biomass concentrations are considered as the initial conditions of the next batch (the initial biomass concentration of the first batch is 0.1 × 10^6^ cells/mL). The culture time is approximately 15 days and one medium renewal is performed approximately after one week. Measurements are taken once every day.

The culture medium is based on 10% FBS (ThermoFischer, Waltham, MA, USA) added to DMEM (Lonza, Belgium) with 6 g/L of glucose and 4 mM of [l]{.smallcaps}-glutamine, and is replaced at a specific time (approximately after one week) when one of the substrates (glucose and glutamine) is exhausted, in order to avoid starving. Most of the times, due to the selected medium composition, glutamine is the limiting substrate. As glucose measurement can be performed relatively quickly with respect to the other analytical methods, medium refreshments are achieved based on glucose concentration evolution. Indeed, when glutamine vanishes, glycolysis stops and glucose is not oxidized anymore. Once this phenomenon is observed, the medium is replaced within the day.

Concerning the culture basic parameters, pH medium is set between 7.2--7.6 at the beginning of the batch and decreases to a minimum of pH between 6.7 and 7.0. The temperature is regulated at 37 °C in a 5% CO~2~ incubator.

3.2. Measurements and Data Sets {#sec3dot2-bioengineering-04-00017}
-------------------------------

Measurements are collected off-line following different methods with respect to the component/analyte: Biomass: Living and dead biomasses are measured by cell-counting using Trypan blue and a Neubauer chamber.Glucose concentration is measured by using a Roche glycemic analytical device called Accu-Chek allowing a fast calculus of the glucose concentration within a few seconds.Lactate concentration is also measured using a Roche device called Accutrend delivering fast concentration measurements using dipsticks.A "Mega-Calc" enzymatic kit from Megazyme is used to obtain the glutamine and ammonium concentrations. This method is based on absorbance measurements.Antibody concentration is obtained using an ELISA dosage of murine IgG designed by the CER group from Aye (Belgium) based on reactants from Bethyl Laboratories (ref A90-131A for coatage antibodies and A90-131P for revelation).

The resulting data are shown in [Figure 2](#bioengineering-04-00017-f002){ref-type="fig"} and [Figure 3](#bioengineering-04-00017-f003){ref-type="fig"}. As apparent, cell viability decreases significantly after four days but is maintained around 30% thanks to the medium replacement. The level of ammonium concentration is very low and ranges below the sensitivity level of the measurement method. Therefore, ammonium is not considered in the modeling study since concentrations are far below the growth-inhibiting level. Only the glucose overflow, producing lactate, will be taken into account.

4. Data-Driven Model Derivation {#sec4-bioengineering-04-00017}
===============================

4.1. Data Processing {#sec4dot1-bioengineering-04-00017}
--------------------

Before applying MLPCA to the data sets, elimination of data outliers should be achieved in order to reject measurement inconsistencies. For instance, the last increasing glutamine concentration measurements of HB1 third experiment should not be used in identification (and direct validation) since glutamine production is not possible.

Even if part of the data is discarded for identification, all the measurements can be considered in cross-validation. In the next sections, the first two sets of HB1 data are selected for identification, and the rest of data for cross-validation.

4.2. MLPCA-Based Systematic Procedure {#sec4dot2-bioengineering-04-00017}
-------------------------------------

The methodology presented in [Section 2.2](#sec2dot2-bioengineering-04-00017){ref-type="sec"} is now applied to the first two data sets of HB1.

As shown in [Figure 4](#bioengineering-04-00017-f004){ref-type="fig"}, a 3-dimensional subspace (i.e., *p* = 3 reactions) is sufficient to interpret the data.

The following matrix $\rho$ represents the maximum likelihood principal components defining the subspace basis related to [Figure 4](#bioengineering-04-00017-f004){ref-type="fig"}: $$\rho = \begin{pmatrix}
{- 0.0074} & {0.0317} & {0.4314} \\
{- 0.0173} & {- 0.0045} & {- 0.3108} \\
{0.1366} & {- 0.5955} & {- 0.6581} \\
{0.0169} & {- 0.0404} & {- 0.0561} \\
{- 0.1389} & {0.7778} & {- 0.5300} \\
{- 0.9805} & {- 0.1940} & {- 0.0153} \\
\end{pmatrix}$$

To obtain a biologically-consistent stoichiometric matrix, reaction constraints have to be expressed so as define a matrix G as introduced in Equation (6):(a)The existence of a glycolysis pathway where biomass grows on substrates, producing no lactate and without mortality (${\hat{k}}_{11} = 1$, ${\hat{k}}_{21} = 0$, ${\hat{k}}_{51} = 0$);(b)A sole glucose overflow pathway, according to the absence of ammonium (i.e., of glutamine overflow), where no dead biomass nor antibody is produced (${\hat{k}}_{12} = 1$, ${\hat{k}}_{22} = 0$, ${\hat{k}}_{62} = 0$);(c)A biomass death pathway (${\hat{k}}_{13} = - 1$, ${\hat{k}}_{23} = 1$) theoretically with no substrate or metabolite concentration variations. The latter would represent too many constraints with respect to the available degree of freedom and arbitrarily, only the lactate coefficient is set to zero (${\hat{k}}_{53} = 0$). Indeed, due to the size of G, which is a 3 by 3 matrix, only 3 constraints can be expressed per reaction.

The general constrained problem can be summarized as:

Find $g_{ij} \in \Re$ solving (6), $$i,j \in \left\{ {1,\ldots,M} \right\}$$

*s.t.* $${k_{lj} \in \left\{ {- 1,0,1} \right\}},~{l \in \left\{ {1,\ldots,N} \right\}}$$

In contrast with \[[@B5-bioengineering-04-00017],[@B6-bioengineering-04-00017]\], this case study offers the possibility to explore the scenario where biomass is produced out of several macro-reactions.

A specific $\hat{K}$ matrix related to the constrained problem (8) is provided by (9): $$\hat{K} = \begin{pmatrix}
1 & 1 & {- 1} \\
0 & 0 & 1 \\
{- 3.2892} & {- 19.5802} & {1.9307} \\
{- 0.5219} & {- 1.3757} & {0.0349} \\
0 & {25.4828} & 0 \\
{36.1432} & 0 & {16.4965} \\
\end{pmatrix}$$

Apparently, the glucose and glutamine stoichiometric coefficients in the third reaction (i.e., ${\hat{k}}_{33}$ and ${\hat{k}}_{43}$) are small compared to the sum of their respective values in reactions 1 and 2. A possible scenario is therefore to consider that ${\hat{k}}_{33}$ and ${\hat{k}}_{43}$ could be set to zero (the coefficient deviations is partly explained by the lack of information in the data and the measurement noise).

The corresponding reaction scheme becomes:

Substrate oxidation: $$\left| {\hat{k}}_{31} \right|G + \left| {\hat{k}}_{41} \right|Gn\overset{\phi_{1}}{\rightarrow}X + {\hat{k}}_{61}MAb$$

Substrate overflow: $$\left| {\hat{k}}_{32} \right|G + \left| {\hat{k}}_{42} \right|Gn\overset{\phi_{2}}{\rightarrow}X + {\hat{k}}_{52}L$$

Biomass death: $$X\overset{\phi_{3}}{\rightarrow}X_{d} + {\hat{k}}_{63}MAb$$ where $\phi_{1}$, $\phi_{2}$ and $\phi_{3}$ are the reaction rates introduced in [Section 5.1](#sec5dot1-bioengineering-04-00017){ref-type="sec"}.

The corresponding mass balance equations are: $$\frac{dX}{dt} = (\phi_{1} + \phi_{2} - \phi_{3})X$$ $$\frac{dX_{d}}{dt} = \phi_{3}X$$ $$\frac{dG}{dt} = - k_{31}\phi_{1} - k_{32}\phi_{2}$$ $$\frac{dGn}{dt} = - k_{41}\phi_{1} - k_{42}\phi_{2}$$ $$\frac{dL}{dt} = k_{52}\phi_{2}$$ $$\frac{dMAb}{dt} = k_{61}\phi_{1} + k_{63}\phi_{3}$$

Compared to published models such as \[[@B3-bioengineering-04-00017]\], the number of reactions is reduced. This can be explained by the absence of ammonium and the related overflow mechanism. As our procedure is data-driven, it leads to the identification of the sole phenomena visible in the collected experimental data.

Moreover, our strategy allows to decouple the identification of the stoichiometry from the kinetics or, at least, to get a first estimate of the stoichiometric parameters, independently of the kinetics. This can be an important asset when identifying bioprocess complex models with numerous parameters.

5. Parameter Identification {#sec5-bioengineering-04-00017}
===========================

5.1. Reaction Rates {#sec5dot1-bioengineering-04-00017}
-------------------

Since the double bottleneck glucose-glutamine is reduced to a simple bottleneck depending on both substrates, a reaction rate combining Monod factors is selected $$\phi_{1} = \min\left( \phi_{G},\phi_{G\max} \right)$$ $$\phi_{2} = \max\left( 0,\phi_{G} - \phi_{G\max} \right)$$ where $$\phi_{G} = \mu_{\max 1}\frac{G}{K_{G} + G}\frac{Gn}{K_{Gn} + Gn}X$$ $$\phi_{G\max} = \mu_{\max 2}X$$ while the death rate is given by $$\phi_{3} = \mu_{d\max}\frac{K_{Gd}}{K_{Gd} + G}\frac{K_{Gnd}}{K_{Gnd} + Gn}X$$

5.2. Initial Conditions and Identification Criterion {#sec5dot2-bioengineering-04-00017}
----------------------------------------------------

Starting with the previously obtained values of the stoichiometric matrix $\hat{K}$ in (10a--10c) as stoichiometric parameter initial conditions, the whole parameter set (i.e., stoichiometric and kinetic parameters) can be identified minimizing a least-squares criterion measuring the distance between model simulated data $\xi_{m}$ and experimental measurements $\xi_{\exp}$ as in: $$J(\theta) = \left( {\xi_{m}(\theta) - \xi_{\exp}(\theta)} \right)^{T}Q^{- 1}\left( {\xi_{m}(\theta) - \xi_{\exp}(\theta)} \right)$$ where $\theta = \left\lbrack {\mu_{\max 1}\mu_{\max 2}K_{G}K_{Gn}K_{Gd}K_{Gnd}\mu_{d\max}k_{31}k_{41}k_{61}k_{32}k_{42}k_{52}k_{63}\xi_{0}} \right\rbrack$ is the parameter vector initialized with $\theta_{0} = \left\lbrack {\mu_{\max 1,0}\mu_{\max 2,0}K_{G,0}K_{Gn,0}K_{Gd,0}K_{Gnd,0}\mu_{d\max,0}{\hat{k}}_{31}{\hat{k}}_{41}{\hat{k}}_{61}{\hat{k}}_{32}{\hat{k}}_{42}{\hat{k}}_{52}{\hat{k}}_{63}\xi_{0,0}} \right\rbrack$. The initial state $\xi_{0}$ is a vector of length $N.n_{\exp}$ with $n_{\exp}$ being the number of experiments used in identification. $\xi_{0,0}$ is set using the experimental measurements at time *t* = 0.

Q is the measurement error covariance matrix. As measurement error standard deviations are a priori unknown, it is common choice to set Q to a diagonal matrix with the squares of the maximum respective concentration levels. This allows to normalize the distances calculated in (16) and give equal importance to states with different orders of magnitude.

Parameter identification is performed with the MATLAB library-optimizer "fmincon". This algoritm allows to set box constraints on the parameters so as to limit the search space, and is typically used here in three successive calls. The first call starts from the initial guess (the MLPCA estimates of the stoichiometry, and an "inspired guess" for the kinetics), and the next are initialized with the parameter values resulting from of the previous minimization. Clever initialization is essential in reducing the computational cost and in increasing the chance of capturing the global minimum.

5.3. Minimization and Multi-Start Strategy {#sec5dot3-bioengineering-04-00017}
------------------------------------------

A multi-start strategy is applied in order to check if convergence is achieved when starting from different locations in the 7-dimensional kinetic parameter space polytope bounded by vertices defined in [Table 1](#bioengineering-04-00017-t001){ref-type="table"}, and to identify the best parameter set corresponding to the cost Function (16) global minimum.

25 runs were achieved, leading to the results shown in [Table A1](#bioengineering-04-00017-t004){ref-type="table"} in [Appendix A](#app1-bioengineering-04-00017){ref-type="app"}. From a quantitative point of view, the minimization process is achieved efficiently in most of the cases since the cost function residuals are comprised in the interval $J_{res} = \begin{bmatrix}
1.1431 & 1.5686 \\
\end{bmatrix}$ in 22 out of the 25 runs (the initial order of magnitude of J is typically between 20 and 100). Runs 11, 16 and 21 lead respectively to $J_{res} = 6.7252$, $J_{res} = 4.1909$ and $J_{res} = 2.8027$, which are highlighted in [Table A1](#bioengineering-04-00017-t004){ref-type="table"} in [Appendix A](#app1-bioengineering-04-00017){ref-type="app"} (large deviations in the value of the growth rate are observed). We can conclude that the neighborhood of the optimum should be reached in almost 90% of the runs based on random initialization inside the polytope.

Interestingly, all the 22 runs lead to similar direct validation results shown in [Figure 5](#bioengineering-04-00017-f005){ref-type="fig"}. For the sake of space in this article, both experiments are graphed on the same figure and the second experiment starts after 15 days, i.e. when the first one is over. Overall, the model predicts well the experimental measurements. However, the prediction of antibody concentration is less accurate after the medium renewal at day 8, probably due to inaccurate biomass concentration measurements.

6. Parametric Sensitivity Analysis {#sec6-bioengineering-04-00017}
==================================

The evaluation of parametric sensitivities, i.e., the relative influence of the parameters on the model outputs, is useful to assess potential identifiability problems and confidence intervals. Identifiability depends on the model structure and parametrization as well as on the information content of the data. In unfavorable situations a lack of sensitivity could appear or correlation among parameters. When the model is identifiable with the data at hand, sensitivity information can be used to evaluate the Fisher Information Matrix (FIM) and in turn confidence intervals for the several parameters \[[@B20-bioengineering-04-00017]\].

6.1. Parameter Error Covariance {#sec6dot1-bioengineering-04-00017}
-------------------------------

The sensitivity of the *i*th state $\xi_{i}$ with respect to *k*th parameter $\theta_{k}$ at time *t* is theoretically defined by: $$\xi_{\theta,i}(t) = \frac{\partial\xi_{i}(t)}{\partial\theta_{k}}$$

Parametric sensitivities can be computed by integration of the following ordinary differential equations: $${\overset{˙}{\xi}}_{\theta,i} = \frac{\partial f_{i}}{\partial\xi_{i}}\xi_{\theta,i} + \frac{\partial f_{i}}{\partial\theta}$$ with ${\overset{˙}{\xi}}_{i} = f_{i}$ the model state equation.

Parameter identifiability can be assessed using the Fisher Information Matrix (*FIM*), which can be computed as follows $$FIM = {\sum\limits_{t_{k} = 1}^{n_{meas}}{\xi_{\theta,i}{(t_{k},\hat{\theta})}^{T}Q^{- 1}\xi_{\theta,i}(t_{k},\hat{\theta})}}$$ where $t_{k}$ is the sampling time and $n_{meas}$ is the number of samples.

An optimistic estimate of the parameter estimation error covariance matrix can be estimated based on the inverse of the *FIM*: $$\hat{P} > \sigma^{2}FIM^{- 1}$$ with $\sigma^{2}$ being the posterior estimate of the measurement error variance obtained from the residual cost function at the optimum: $$\sigma^{2} = \frac{J^{*?}}{N_{meas} - n_{\theta}}$$ where $N_{meas}$ is the total number of measurements $\left( {N_{meas} = n_{meas}N} \right)$ and $n_{\theta}$ is the number of estimated parameters.

6.2. Application to the Case Study {#sec6dot2-bioengineering-04-00017}
----------------------------------

The relative standard deviations (the square root of the diagonal of (20)) are shown in [Table A2](#bioengineering-04-00017-t005){ref-type="table"} in [Appendix A](#app1-bioengineering-04-00017){ref-type="app"} for the 22 optimization runs under consideration. It is apparent that the error on $K_{G}$ is very large, which is a sign that model (11) is over-parameterized. Indeed, glucose concentration levels are low so that $\frac{G}{G + K_{G}} \approx 1$.

7. Reduced Model Identification {#sec7-bioengineering-04-00017}
===============================

7.1. Model Reduction {#sec7dot1-bioengineering-04-00017}
--------------------

Expression (13) is simplified to: $$\phi_{G} = \mu_{\max 1}\frac{Gn}{K_{Gn} + Gn}X$$

Since glutamine is the main nitrogen source dedicated to cell viability, it is not surprising that glutamine becomes responsible of cell growth, i.e. glycolysis and overflow.

7.2. Re-Identification {#sec7dot2-bioengineering-04-00017}
----------------------

With the exception of a few local minima, multi-start identification again leads the minima in the range $J_{res} = \begin{bmatrix}
1.1087 & 1.6534 \\
\end{bmatrix}$ and direct validation is shown in [Figure 6](#bioengineering-04-00017-f006){ref-type="fig"}.

Relative standard deviations are much improved as shown in [Table 2](#bioengineering-04-00017-t002){ref-type="table"}, only for the best run (i.e., presenting the best cost function and relative error standard deviations).

7.3. Reduced Model Cross-Validation {#sec7dot3-bioengineering-04-00017}
-----------------------------------

The third data set of HB1 is now used to cross-validate the identified model. During this cross-validation, initial states are re-estimated since initial measurement noise can be a critical source of result degradation. Results shown in [Figure 7](#bioengineering-04-00017-f007){ref-type="fig"} are quite satisfactory even though the antibody concentration still suffers from discrepancies after medium renewal. It is worth noticing that the last 3 measurements of glutamine concentration are probably outliers following wrong analytical manipulations (glutamine is only consumed and cannot be produced).

The residual deviation between the model and the experimental data is given by $J_{res} = 1.3573$.

Interestingly, the model is also able of a relatively good prediction of the experimental data collected with the second hybridoma strain shown in [Figure 8](#bioengineering-04-00017-f008){ref-type="fig"}. The main discrepancy is in the prediction of the biomass (and consequently of the antibody concentration). However, residuals are still relatively low ($J_{res} = 1.4774$), confirming the satisfactory results. These observations allow the perspective that macroscopic models could be adapted from one application to another at relatively little extra costs, just recalibrating the model based on some new available data, starting from the parameter estimates obtained in earlier applications.

7.4. Robustness to Parameter Uncertainty {#sec7dot4-bioengineering-04-00017}
----------------------------------------

Since the identified parameters of [Section 7.2](#sec7dot2-bioengineering-04-00017){ref-type="sec"} show some uncertainties represented by their estimation error standard deviations (see [Table 2](#bioengineering-04-00017-t002){ref-type="table"}), a Monte-Carlo analysis is developed, where each parameter is subject to normally distributed variations.

100 runs of the HB1 model are performed for the HB1 cross-validation data sets and are shown in [Figure 9](#bioengineering-04-00017-f009){ref-type="fig"}. The trajectory envelope is most of the time contained within the measurement confidence intervals with the exception of the MAb measurements following the medium renewal.

Results of the Monte-Carlo analysis are presented in [Table 3](#bioengineering-04-00017-t003){ref-type="table"}.

Parameter variations can have a slight positive effect on cross validation (since the residual cost function was initially 1.3573 and the best Monte-Carlo case is 1.3412) but usually a negative effect, the worst case corresponding to a residual cost of 1.6225. Since all the runs provide satisfactory results, the identified model is quite acceptable for prediction and control purposes.

8. Optimization of the Monoclonal Antibody Production {#sec8-bioengineering-04-00017}
=====================================================

This section intends to provide the best medium renewal time and composition to maximize the monoclonal antibody production and substrate savings. Using the validated model of [Section 7](#sec7-bioengineering-04-00017){ref-type="sec"}, it is possible to express these targets in a mathematical objective function of the form: $$J_{obj} = MAb{(t_{renewal})}^{2} + MAb{(t_{f})}^{2} - \alpha(G_{renewal}^{2} + Gn_{renewal}^{2})$$ where α represents a weighting coefficient penalizing substrate savings with respect to MAb production, i.e. defining the degree of predominance of one target over the other. Minimization of (25) is achieved using the optimizer *fmincon* from the Matlab platform, in order to find the best values of θ = \[t~renewal~ G~renewal~ Gn~refresh~\], i.e., is the medium renewal time t~renewal~ and the glucose and glutamine concentrations in the medium G~renewal~ and Gn~renewal~. *Fmincon* also allows to specify box constraints for t~renewal~ Є \[3 14\] days. These values are selected in accordance with the previous experimental results: medium renewal should on the one hand not occur too soon and on the other hand before the end of the experiment set at day 14. G~renewal~ Є \[1 15\] g/L and Gn~renewal~ Є \[0.1 1\] g/L so as to avoid cell starvation or growth inhibition through the accumulation of byproduct.

[Figure 10](#bioengineering-04-00017-f010){ref-type="fig"} shows the optimization results when α is set to zero and G~renewal~ and Gn~renewal~ are respectively set to 6 and 0.4 g/L (which is similar to the concentrations used in the experiments dedicated to model identification described in [Section 7](#sec7-bioengineering-04-00017){ref-type="sec"}). The best time at which medium renewal should be achieved is found at t~renewal~ = 4.54 days (in the previous experiments, renewal had been achieved after approximately 7 days). Moreover, the MAb production, defined as the sum of the final batch concentrations, amounts to 60.92 µg/mL which represents a production gain of 30% with respect to the experiments of [Figure 1](#bioengineering-04-00017-f001){ref-type="fig"} (where the production can be estimated to 40 to 45 µg/mL).

[Figure 11](#bioengineering-04-00017-f011){ref-type="fig"} shows new results when a strong emphasis is placed on substrate savings with α = 10. The optimizer converges to θ = \[6.95 4.55 1\], which leads to the following observations:Even when considering substrate savings, the upper bound of Gn~refresh~ is reached. Indeed, when G is depleted, Gn still limits biomass decay and therefore maintains an efficient MAb production rate. However, since ammonium production (byproduct formed by glutamine overflow) is not considered in the model obtained in [Section 7](#sec7-bioengineering-04-00017){ref-type="sec"}, higher values of Gn~refresh~ are not recommended.Interestingly, approximately the same renewal time as in [Figure 2](#bioengineering-04-00017-f002){ref-type="fig"} is obtained, which means that these experiments could be "economically" optimized only by revising the medium composition.

Since MAb production clearly appears as a function of substrate saving penalization, new optimizations considering α in the range 0 to 500 with incremental steps of 50 are achieved in order to assess the impact of α on MAb production and select a good compromise. Results displayed in [Figure 12](#bioengineering-04-00017-f012){ref-type="fig"} show that specific operating conditions can be chosen to reach a target MAb production. For instance, approximately 3 g/L of glucose are sufficient, with a renewal after 4 days, to harvest 75 µg/mL of MAb within 14 days. Moreover, operating conditions of [Figure 2](#bioengineering-04-00017-f002){ref-type="fig"} seem to be a good economic compromise as 100 µg/mL can be harvested starting with a glucose concentration of 6 g/L and a renewal after 7 days. Concerning the glutamine concentration, the observations from [Figure 10](#bioengineering-04-00017-f010){ref-type="fig"} are confirmed: since no glutamine overflow is considered, very high glutamine concentrations are unrealistically tolerated.

9. Conclusions {#sec9-bioengineering-04-00017}
==============

In this work, a simple dynamic model of hybridoma sequential batch cultures is developed, which can be used to optimize the production of monoclonal antibodies.

Maximum likelihood principal component analysis allows assessing the information content of the experimental data, providing the minimum number of reactions and the corresponding stoichiometry by solving an optimization problem under a few a priori biological constraints. An original formulation of the method is presented, allowing biomass to occur in several reactions.

Advantages of the method are (a) to limit the number of reactions, i.e. to avoid a useless complication of the model with respect to the experimental field and the involved biological phenomena (activation, saturation, inhibition, etc.); (b) to offer the possibility to proceed to a quick first estimation of the stoichiometry independently of the kinetics, in turn reducing the number of unknown parameters (for the current model, stoichiometry represents half the parameter set); (c) to provide a "divide and conquer" approach where the stoichiometry and kinetics can be estimated separately or simultaneously, in an iterative way, starting from estimates obtained at the previous step.

The procedure can be supplemented by parametric sensitivity analysis, which allows further model simplification, whenever needed, by isolating parameters with low sensitivities.

A Monte-Carlo study, where parameter variations are considered in accordance with the resulting estimation error variances, shows that model trajectories are globally kept inside a corridor defined by measurement confidence intervals (i.e., parameter discrepancies do not cause critical model misevaluations).

As a practical illustrative outcome of the present study, the obtained dynamic model is used for a two-sequential batch process optimization (determination of the best sequence and composition of medium renewals). The results show that the importance of substrate savings drives the location of the optimum. A renewal time scheduling can therefore be established based on the user will to save medium components such as substrates. Further experimental validations of the optimization method are important perspectives of this still on-going work as well as estimation and on-line control issues.

This paper presents research results of the Belgian Network DYSCO (Dynamical Systems, Control, and Optimization), funded by the Interuniversity Attraction Poles Programme, initiated by the Belgian State, Science Policy Office. The authors acknowledge the support of the MabDrive project in the convention *no* 1410085, achieved in collaboration with the CER Groupe. The scientific responsibility rests with its author(s).
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###### 

Parameter identification following the 25 multi-start runs (orange lines indicate clear local minima).

  ---------------- ---------------- --------- ---------- ---------- ----------- --------------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  $\mu_{\max 1}$   $\mu_{\max 2}$   $K_{G}$   $K_{Gn}$   $K_{Gd}$   $K_{Gnd}$   $\mu_{d\max}$   $k_{31}$   $k_{32}$   $k_{41}$   $k_{42}$   $k_{52}$   $k_{61}$   $k_{63}$
  0.5559           0.1410           0.1456    0.0224     2.1895     0.1922      0.7028          2.4175     6.0250     1.2867     0.5061     10.6769    119.7005   7.6599
  0.5880           0.2670           0.0451    0.0162     1.9315     1.1321      0.7073          2.3867     6.6606     0.7739     0.6705     14.6022    68.0054    7.7126
  0.5547           0.1500           0.0115    0.0094     1.2845     1.2627      0.9401          4.2541     4.4612     0.4948     0.8604     9.6828     114.3043   9.5609
  0.5473           0.1429           0.0280    0.0145     1.9152     0.3041      0.7235          2.8453     6.0009     0.7705     0.7854     10.3002    122.0962   10.2667
  0.6058           0.0611           0.0526    0.0413     0.8423     0.9630      1.2922          4.2558     5.7751     2.0796     0.5338     8.1830     234.9037   14.3253
  0.5626           0.1100           0.0521    0.0286     0.9322     0.3854      1.2512          3.2340     5.6626     1.5257     0.4498     9.6220     161.7081   4.3626
  0.5887           0.2774           0.0273    0.0170     2.3108     1.7476      0.6160          2.7446     8.1550     0.8308     0.5936     15.0889    62.0973    10.5890
  0.6303           0.1737           0.0988    0.0229     2.0640     2.0451      0.6517          2.7454     6.1184     1.0883     0.5328     10.1684    94.7350    13.3752
  0.6139           0.2062           0.1491    0.0195     1.0761     1.6163      1.0645          2.8275     6.4991     0.9660     0.5718     11.4731    78.7716    13.9319
  0.5195           0.2916           0.0223    0.0061     2.5413     0.3398      0.6242          3.9897     5.4858     0.3507     1.5180     18.3348    65.0805    5.7034
  0.2676           0.5515           0.0170    0.0123     1.8476     1.9618      0.1667          3.5684     13.6956    1.4072     1.3057     15.4667    107.3452   17.9771
  0.6048           0.1698           0.0305    0.0232     2.0572     0.7868      0.6622          3.5670     5.3198     1.1648     0.5179     10.4758    104.5675   9.7748
  0.5868           0.1808           0.0329    0.0219     2.4127     1.7841      0.6059          3.3243     5.3469     1.0981     0.4273     10.7470    94.6231    7.8496
  0.5865           0.1951           0.0285    0.0185     1.1563     0.6525      1.0732          2.5100     4.3891     0.8773     0.6274     11.3024    98.2351    3.4642
  0.5287           0.2558           0.0744    0.0099     2.4822     2.1080      0.6520          5.1365     4.3431     0.6706     0.8310     16.4441    59.0160    12.3303
  0.9859           0.6572           0.0100    0.1800     5.7454     2.3415      0.3338          7.0345     0.2045     0.8892     0.0953     0.0064     50.4414    0.0511
  0.5609           0.2443           0.0260    0.0116     0.8086     0.6322      1.3976          2.7069     6.8815     0.5485     0.9639     13.8020    76.5734    6.3556
  0.6099           0.0984           0.1118    0.0176     2.1902     1.6137      0.6266          2.4999     5.1055     0.8327     0.7344     8.4616     146.6756   18.1001
  0.6311           0.1634           0.0090    0.0452     1.2904     1.3282      0.8407          0.5745     9.7854     1.9713     0.1358     10.8829    126.9890   0.2194
  0.5854           0.1725           0.1799    0.0251     1.7937     0.2995      0.7516          2.8422     6.3408     1.2724     0.4102     11.3594    101.7783   8.0611
  0.3523           0.1682           0.2644    0.0147     0.2683     0.2306      0.3314          3.5112     17.5043    0.9900     1.5072     27.5654    98.4703    16.7248
  0.5577           0.3183           0.0328    0.0073     1.6475     1.3849      0.8834          2.8735     5.5942     0.4435     1.1310     17.5563    6.7974     47.0452
  0.6057           0.2115           0.0757    0.0163     1.5704     1.5814      0.8071          2.4129     5.6236     0.7583     0.6688     11.0633    87.1816    7.4376
  0.5954           0.1964           0.0197    0.0171     1.2385     0.7389      0.9992          2.3813     5.4283     0.7576     0.7362     11.0359    100.4704   3.6202
  0.5482           0.2715           0.0400    0.0182     1.5790     0.2627      0.8576          6.9704     1.5800     1.0154     0.3502     17.0623    67.7835    6.2548
  ---------------- ---------------- --------- ---------- ---------- ----------- --------------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
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###### 

Parameter estimation error relative standard deviations for the 22 selected runs.

  ---------------- ---------------- ----------- ---------- ---------- ----------- --------------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  $\mu_{\max 1}$   $\mu_{\max 2}$   $K_{G}$     $K_{Gn}$   $K_{Gd}$   $K_{Gnd}$   $\mu_{d\max}$   $k_{31}$   $k_{32}$   $k_{41}$   $k_{42}$   $k_{52}$   $k_{61}$   $k_{63}$
  3.6662           22.6437          130.2128    17.8640    49.5212    13.2501     31.2599         120.2970   24.7702    21.8237    16.9119    10.8063    22.3173    22.0970
  3.1545           11.4168          361.2676    18.2503    55.3056    40.4276     36.8463         57.3265    26.6477    11.5497    15.0769    12.9871    11.3732    22.5188
  2.7529           27.1667          1181.2541   23.8344    46.7243    43.2328     34.3950         73.5869    32.0299    30.7479    11.1012    12.1905    27.1262    20.1369
  3.6238           24.3889          720.1689    20.7425    59.3874    18.0344     39.2357         103.7392   24.0107    24.4068    11.3759    11.0635    24.1557    17.9644
  5.1282           46.0975          628.3497    18.5780    114.7653   46.7917     93.0397         126.2801   16.7504    42.9210    10.6211    8.0060     45.4639    15.6957
  3.6607           27.9484          379.5510    17.5197    73.0553    20.8103     57.9583         107.1231   22.6208    26.9998    16.0283    9.7616     27.6345    44.1384
  3.0754           11.0214          574.9346    18.7735    51.3645    61.7058     31.3976         48.8369    23.7644    10.9953    17.3372    13.4790    10.9730    16.2965
  3.7369           19.7116          211.5824    17.6190    54.5606    71.9202     34.9982         83.7420    21.9111    18.2301    14.1168    10.5920    19.4313    13.2615
  3.8635           16.5377          145.3122    18.6602    84.8642    60.1199     65.9035         69.0624    23.7561    15.6449    15.0802    11.7848    16.3232    12.8728
  2.5121           10.8171          546.0726    24.6565    49.0097    18.0168     29.2449         32.5452    39.8743    17.6116    15.2724    16.7534    10.9220    30.5888
  3.5450           19.6658          640.1403    17.3780    54.9197    32.1188     35.3471         67.2044    25.6640    18.4603    15.0928    10.6327    19.3963    17.6762
  3.9618           18.6565          667.0940    18.3143    57.4314    68.1850     34.5779         65.4403    26.6676    17.9300    18.1388    11.5034    18.5005    24.8874
  3.4707           16.9881          644.5080    17.9580    71.5894    26.5994     55.1697         79.9299    32.5613    16.7107    13.7367    11.4200    16.8977    52.9654
  4.2695           14.5552          280.6340    24.0336    59.1986    67.5103     36.0739         34.9784    50.1691    15.7086    18.0133    17.5370    14.6961    16.8627
  3.0381           13.3080          609.3884    20.3656    87.6372    27.4640     72.0226         57.3727    25.6625    15.4098    12.4396    13.1777    13.3089    27.3362
  3.7332           36.3680          186.6357    20.3580    49.4555    58.1809     31.1673         159.1482   21.3178    32.7821    9.1231     9.4398     35.9587    11.4881
  3.3887           16.9274          1933.8346   15.1813    69.0932    49.6417     50.7343         401.5180   14.7875    16.6962    52.5206    9.3112     16.6627    722.5528
  3.5640           17.3184          110.6870    17.5278    61.0394    17.2553     41.0509         77.7436    23.3178    16.9096    19.8023    10.6291    17.0292    21.2591
  3.2513           12.6435          484.7580    27.1346    58.2372    46.5384     40.9441         46.2395    44.1952    15.8306    17.7920    20.7195    25.5029    4.2209
  3.4716           16.2920          247.1369    18.5861    60.9806    55.8643     43.1792         76.6727    26.1026    16.0291    12.9251    11.8084    16.2252    24.4574
  3.2776           16.8715          871.4772    17.9683    61.5156    28.8860     46.3341         82.1495    25.7187    16.8224    11.7135    11.0761    16.8066    49.3217
  3.0620           10.1596          397.7225    18.8584    77.1272    16.8420     54.2770         20.9435    121.3063   10.1811    31.2955    13.8143    9.9632     24.4122
  ---------------- ---------------- ----------- ---------- ---------- ----------- --------------- ---------- ---------- ---------- ---------- ---------- ---------- ----------

![Schematic representation of the bottleneck assumption of Sonnleitner and Käppeli \[[@B12-bioengineering-04-00017]\].](bioengineering-04-00017-g001){#bioengineering-04-00017-f001}

![HB1 sequential batch culture data sets. Medium refreshment times are indicated by the arrows.](bioengineering-04-00017-g002){#bioengineering-04-00017-f002}

![HB2 sequential batch culture data sets. Medium refreshment times are indicated by the arrows.](bioengineering-04-00017-g003){#bioengineering-04-00017-f003}

![Log-likelihood costs of the p-dimensional subspaces of the first two HB1 data sets. The upper dashed line represents the chi-square quantile χ${}_{28x6}^{2}$ at 99.9% and the lower one the chi-square quantile χ${}_{28x6}^{2}$ at 0.1%.](bioengineering-04-00017-g004){#bioengineering-04-00017-f004}

![Direct validation of Model (11) on the first two data sets of the HB1 strain. The second experiment starts after 15 days. The solid line represents the model prediction while the circles represent the experimental measurements with a confidence interval at 99%.](bioengineering-04-00017-g005){#bioengineering-04-00017-f005}

![Direct validation of the reduced model with the first two data sets of the HB1 strain. The second experiment starts after 15 days. The solid line represents the model while the circles represent the experimental measurements with a confidence interval at 99%.](bioengineering-04-00017-g006){#bioengineering-04-00017-f006}

![Cross-validation of the reduced model on the third data set of the HB1 strain. The solid line represents the model while the circles represent the experimental measurements with a confidence interval at 99%.](bioengineering-04-00017-g007){#bioengineering-04-00017-f007}

![Cross-validation with the second data set of the HB2 strain of the reduced model identified with HB1 data sets. The solid line represents the model while the circles represent the experimental measurements with a confidence interval at 99%.](bioengineering-04-00017-g008){#bioengineering-04-00017-f008}

![Monte-Carlo analysis of the cross validation of the HB1 model: the solid lines represent 100 model trajectories corresponding to normally distributed parameters characterized by the standard deviations of [Table 3](#bioengineering-04-00017-t003){ref-type="table"}. Circles represent the experimental measurements with a confidence interval of 99%.](bioengineering-04-00017-g009){#bioengineering-04-00017-f009}

![Optimization of the renewal time with medium substrate concentrations respectively set to G = 6 g/L and Gn = 0.4 g/L (α = 0), while maximizing monoclonal antibody production.](bioengineering-04-00017-g010){#bioengineering-04-00017-f010}

![Optimization of the renewal time when an important substrate saving (α = 10) to maximize the produced monoclonal antibody amount.](bioengineering-04-00017-g011){#bioengineering-04-00017-f011}

![Evolution of the culture operating conditions and MAb production as functions of α.](bioengineering-04-00017-g012){#bioengineering-04-00017-f012}
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###### 

Vertices of the multi-start parameter polytope.

  Kinetic Parameters/Min--Max Values   Minimum Initial Value   Maximum Initial Value
  ------------------------------------ ----------------------- -----------------------
  $\mu_{\max 1}$                       0.1 h^−1^               1 h^−1^
  $\mu_{\max 2}$                       0.1 h^−1^               1 h^−1^
  $K_{G}$                              0.01 g/L                1 g/L
  $K_{Gn}$                             0.01 g/L                1 g/L
  $K_{Gd}$                             0.1 g/L                 10 g/L
  $K_{Gnd}$                            0.1 g/L                 10 g/L
  $\mu_{d\max}$                        0.1 h^−1^               1 h^−1^
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###### 

Parameter estimates and relative estimation error for the best identification run of the reduced model.

  Parameter                  Relative Error Standard Deviation
  ---------------- --------- -----------------------------------
  $\mu_{\max 1}$   0.4849    1.7652
  $\mu_{\max 2}$   0.3198    8.1283
  $K_{Gn}$         0.0089    23.2540
  $K_{Gd}$         1.5899    15.4666
  $K_{Gnd}$        1.3359    49.2893
  $\mu_{d\max}$    0.8667    66.5216
  $k_{31}$         3.1207    34.1265
  $k_{32}$         15.2090   26.3604
  $k_{41}$         0.6245    9.5667
  $k_{42}$         1.2221    19.2377
  $k_{52}$         23.9586   20.3273
  $k_{61}$         43.5907   8.3527
  $k_{63}$         14.2221   10.9999
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###### 

Results of the Monte-Carlo analysis: number of runs, minimum, maximum and mean values of the residual cost function *J* and standard deviation.

  Runs   Min J    Max J    J Mean   J Std Deviation
  ------ -------- -------- -------- -----------------
  100    1.3412   1.6225   1.4050   0.0576
